New Haven, Conn. —Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, has been elected as one of four new Translational Science Representatives serving on the Thoracic Malignancy Steering Committee (TMSC) for the National Cancer Institute (NCI). In addition, Dr. Herbst is a Professor of Internal Medicine (Medical Oncology) and Pharmacology at Yale School of Medicine, Associate Director for Translational Science at Yale Cancer Center, and Clinical Program Leader for the Thoracic Oncology Clinical Research Program at Smilow Cancer Hospital.
“I am honored to serve the National Cancer Institute on the Thoracic Malignancy Steering Committee and look forward to working with the committee to advance the treatment of lung cancer through strategic support of translational research efforts and cutting edge clinical trials,” Dr. Herbst said.
The TMSC was established in 2008 to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the “Best Science” in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase III clinical trials and large phase II studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma.
Dr. Herbst received his medical degree from Cornell University Medical College and earned a PhD in molecular cell biology from the Rockefeller University. He completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.
Yale Cancer Center is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Smilow Cancer Hospital at Yale-New Haven and Yale School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.
Contact: Renee Gaudette email@example.com
This Article was submitted by Renee Elizabeth Gaudette, on Thursday, July 19, 2012.